跳到正文
原文
Endpoints News 生物医药· Ayisha Sharma·· 2026-10-13AI 评分25

Syndax 终止 Niktimvo 治疗特发性肺纤维化(IPF)的开发,II 期试验失败

Syndax's lung disease ambitions for Niktimvo end with a Phase 2 failure

AI 导读

Syndax 在 Niktimvo 治疗特发性肺纤维化(IPF)的 II 期试验失败后,终止了该药在该适应症上的开发。此次失败意味着 Niktimvo 不再推进 IPF 适应症。

正文

Syn­dax is end­ing de­vel­op­ment of Nik­tim­vo in a rare lung dis­ease called id­io­path­ic pul­monary fi­bro­sis (IPF) af­ter the treat­ment flunked a mid-stage tri­al.

The com­pa­ny …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news